BriaCell Financial Statements From 2010 to 2025

BCTXW Stock  USD 0.10  0.01  9.09%   
BriaCell Therapeutics financial statements provide useful quarterly and yearly information to potential BriaCell Therapeutics Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BriaCell Therapeutics financial statements helps investors assess BriaCell Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BriaCell Therapeutics' valuation are summarized below:
Market Capitalization
48.1 M
There are over one hundred nineteen available fundamental signals for BriaCell Therapeutics Corp, which can be analyzed over time and compared to other ratios. All traders should should validate BriaCell Therapeutics' prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 1.5 B in 2025. Enterprise Value is likely to climb to about 1.4 B in 2025
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 40.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

BriaCell Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.3 M6.8 M11.3 M
Slightly volatile
Total Current LiabilitiesM8.6 M2.4 M
Slightly volatile
Accounts Payable8.7 M8.2 M1.6 M
Slightly volatile
Cash941.8 K991.4 KM
Slightly volatile
Non Current Assets Total1.2 MM1.5 M
Slightly volatile
Cash And Short Term Investments941.8 K991.4 K8.3 M
Slightly volatile
Common Stock Shares Outstanding19.9 M18.9 M5.8 M
Slightly volatile
Liabilities And Stockholders Equity10.3 M6.8 M11.3 M
Slightly volatile
Non Current Liabilities Total1.2 M1.3 M4.4 M
Slightly volatile
Other Stockholder Equity7.7 M12.7 M8.3 M
Pretty Stable
Total Liabilities10.3 M9.8 M6.4 M
Slightly volatile
Total Current AssetsM4.2 M9.4 M
Slightly volatile
Net Receivables1.7 M1.6 M344.4 K
Slightly volatile
Other Current Liabilities657.3 K333.9 K622.7 K
Pretty Stable
Other Current Assets1.7 M1.6 M865 K
Slightly volatile
Intangible Assets182.9 K229.8 K129.7 K
Slightly volatile
Long Term Investments505.3 K481.3 K87.8 K
Slightly volatile
Short and Long Term Debt Total22.2 K23.4 K602.8 K
Slightly volatile
Long Term Debt22.2 K23.4 K776.2 K
Slightly volatile
Short and Long Term Debt262.4 K276.2 K884.4 K
Slightly volatile
Capital Stock45.8 M83 M29.7 M
Slightly volatile
Short Term Debt195.6 K205.9 K675.7 K
Slightly volatile
Common Stock45.8 M83 M29.7 M
Slightly volatile
Non Current Liabilities Other231.3 K220.3 K88.1 K
Slightly volatile

BriaCell Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses40.2 M38.3 M9.3 M
Slightly volatile
Selling General Administrative7.4 M7.1 MM
Slightly volatile
Research Development32.8 M31.3 MM
Slightly volatile
Interest Income177.7 K331.2 K134.4 K
Slightly volatile
Reconciled Depreciation101.3 K96.5 K24 K
Slightly volatile
Cost Of Revenue16.4 K17.9 K14.9 K
Slightly volatile

BriaCell Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow941.8 K991.4 K8.1 M
Slightly volatile
Stock Based Compensation2.2 M2.1 M982.3 K
Slightly volatile
Depreciation101.3 K96.5 K23.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital622.1 K673.5 K814.6 K
Slightly volatile
Average Payables749.9 K714.2 K248.4 K
Slightly volatile
Capex To Depreciation5.956.26197
Slightly volatile
Cash Per Share1.491.569.114
Slightly volatile
Days Payables Outstanding18.9 K18 K5.6 K
Slightly volatile
Net Current Asset Value357.4 K402 K438.3 K
Slightly volatile
Income Quality4.624.42.4735
Slightly volatile
Tangible Asset Value628.6 K675.2 K823.5 K
Slightly volatile
Intangibles To Total Assets0.03720.03910.0855
Pretty Stable
Current Ratio0.420.4414.4058
Pretty Stable
Graham Number2.913.0649.0294
Slightly volatile
Capex Per Share0.00760.0084.949
Slightly volatile
Average Receivables350.5 K333.8 K102.1 K
Slightly volatile
Interest Debt Per Share1.0E-41.0E-40.3174
Pretty Stable
Debt To Assets5.0E-45.0E-40.3206
Slightly volatile
Payables Turnover0.01990.02110.1264
Slightly volatile
Days Of Payables Outstanding18.9 K18 K5.6 K
Slightly volatile
Long Term Debt To Capitalization4.0E-44.0E-44.0E-4
Slightly volatile
Quick Ratio0.420.4414.1472
Very volatile
Cash Ratio0.09880.111.8884
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.171.6364
Slightly volatile
Debt Ratio5.0E-45.0E-40.3206
Slightly volatile

BriaCell Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 B1.4 B610.2 M
Slightly volatile
Working Capital357.4 K402 K438.3 K
Slightly volatile
Enterprise Value1.4 B1.4 B598.8 M
Slightly volatile

BriaCell Fundamental Market Drivers

Cash And Short Term Investments862.1 K

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.8 K-3.6 K
Cost Of Revenue17.9 K16.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.